日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Assessment of thyroid cancer risk associated with glucagon-like peptide 1 receptor agonist use

评估使用胰高血糖素样肽-1受体激动剂相关的甲状腺癌风险

Vilsbøll, Tina; Stellfeld, Michael; Aroda, Vanita R; Dandanell, Sune; David, Jens-Peter; Kristiansen, Ceyda T P; Rasmussen, Søren; Roberts, Fiona L; Hegedüs, Laszlo

Investigating Endogenous Hypercortisolism Prevalence in a U.S. Population With Resistant Hypertension: MOMENTUM Rationale and Design

调查美国难治性高血压人群中内源性高皮质醇症的患病率:MOMENTUM 研究的理论基础和设计

Plutzky, Jorge; Taub, Pam R; Bhatt, Deepak L; Al Dhaybi, Omar; Aroda, Vanita R; Basile, Jan N; Bloch, Michael J; Budoff, Matthew; Busch, Robert S; Buse, John B; Cheung, Dianne; Christofides, Elena A; DeFronzo, Ralph A; Galindo, Rodolfo J; Handelsman, Yehuda; Laffin, Luke; Parker, John C; Rader, Florian; Rosenstock, Julio; Sloan, Lance A; Tudor, Iulia Cristina; Einhorn, Daniel

Glycaemic control is still central in the hierarchy of priorities in type 2 diabetes management

血糖控制仍然是2型糖尿病管理优先事项的核心。

Khunti, Kamlesh; Zaccardi, Francesco; Amod, Aslam; Aroda, Vanita R; Aschner, Pablo; Colagiuri, Stephen; Mohan, Viswanathan; Chan, Juliana C N

Safety considerations of semaglutide in the potential treatment of Alzheimer's disease: A pooled analysis of semaglutide in adults aged ≥ 65 years

索玛鲁肽在阿尔茨海默病潜在治疗中的安全性考量:一项针对≥65岁成年人的索玛鲁肽汇总分析

Sabbagh, Marwan; Boschini, Cristina; Cohen, Sharon; Fugger, Magnus; Jessen, Frank; Dandanell, Sune; Pedersen, Sue D; Tarazona, Luis Rafael Solís; Aroda, Vanita R

Characteristics of patients prescribed SGLT-2i and/or GLP-1RA among cardiology clinics in the US: insights from the COORDINATE-diabetes trial

美国心脏病诊所中接受SGLT-2抑制剂和/或GLP-1受体激动剂治疗的患者特征:来自COORDINATE-diabetes试验的启示

Nelson, Adam J; Kaltenbach, Lisa A; Al-Khalidi, Hussein R; Leyva, Monica; Webb, Laura; McGuire, Darren K; Pop-Busui, Rodica; Cavender, Matthew A; Aroda, Vanita R; Magwire, Melissa L; Richardson, Caroline R; Lingvay, Ildiko; Kirk, Julienne K; Pandey, Ambarish; Gaynor, Tanya; Pak, Jonathan; Washington, Alana; Senyucel, Cagri; Lopes, Renato D; Green, Jennifer B; Granger, Christopher B; Pagidipati, Neha J

Role of 2-hour plasma glucose in assessing pre-diabetes risk: insights from the vitamin D and type 2 diabetes (D2d) study cohort

餐后2小时血糖在评估糖尿病前期风险中的作用:来自维生素D与2型糖尿病(D2d)研究队列的启示

Kim, Sun H; Aroda, Vanita R; Chatterjee, Ranee; LeBlanc, Erin S; Nelson, Jason; Rasouli, Neda; Staten, Myrlene A; Vickery, Ellen M; Pittas, Anastassios G; Hsia, Daniel S

Time to Treatment Intensification with Glucagon-Like Peptide-1 Receptor Agonists Versus Comparators in People with Type 2 Diabetes Treated with Metformin

在接受二甲双胍治疗的 2 型糖尿病患者中,使用胰高血糖素样肽-1 受体激动剂与对照药物相比,强化治疗所需时间

Ostrominski, John W; Aroda, Vanita R; Braae, Uffe C; Kruse, Christian; Mandavya, Kabirdev; Buse, John B

Effect of Oral Semaglutide Versus Comparators on Multiple Cardiometabolic Risk Factor Control in Adults With Type 2 Diabetes

口服索马鲁肽与对照药物对2型糖尿病成人患者多种心血管代谢危险因素控制的影响

Aroda, Vanita R; Malling, Brian; Meier, Juris J; Abildlund, Morten T; Kelkar, Pranav; Vilsbøll, Tina; Khunti, Kamlesh

High-Dose Semaglutide (Up to 16 mg) in People With Type 2 Diabetes and Overweight or Obesity: A Randomized, Placebo-Controlled, Phase 2 Trial

高剂量索玛鲁肽(最高 16 毫克)治疗 2 型糖尿病合并超重或肥胖患者:一项随机、安慰剂对照的 2 期试验

Aroda, Vanita R; Jørgensen, Nils B; Kumar, Bharath; Lingvay, Ildiko; Laulund, Anne Sofie; Buse, John B

Prevalence of Hypercortisolism in Difficult-to-Control Type 2 Diabetes

难治性2型糖尿病患者中高皮质醇血症的患病率

Buse, John B; Kahn, Steven E; Aroda, Vanita R; Auchus, Richard J; Bailey, Timothy; Bancos, Irina; Busch, Robert S; Christofides, Elena A; DeFronzo, Ralph A; Eilerman, Bradley; Findling, James W; Fonseca, Vivian; Hamidi, Oksana; Handelsman, Yehuda; Miller, Harold J; Ownby, Jonathan G; Parker, John C; Philis-Tsimikas, Athena; Pratley, Richard; Rosenstock, Julio; Shanik, Michael H; Sloan, Lance L; Umpierrez, Guillermo; Tudor, Iulia Cristina; Schlafly, Tina K; Einhorn, Daniel